Lung Cancer | Specialty

Adjuvant Approaches in EGFR+ NSCLC

October 20th 2020

Standard of Care for EGFR+ ES-NSCLC

October 20th 2020

Testing for EGFR in NSCLC Worldwide

October 20th 2020

Molecular Testing in Early-Stage NSCLC

October 20th 2020

Determining Resectability in ES-NSCLC

October 20th 2020

Clinical Evaluation of ES-NSCLC in Japan

October 20th 2020

Pembrolizumab Combos Showcase Promising Safety, Antitumor Activity in NSCLC

October 19th 2020

Pembrolizumab has demonstrated promising activity when used in combination with chemotherapy or quavonlimab in select patients with nonsquamous or advanced non–small cell lung cancer.

Trilaciclib Reduces Need for G-CSF, RBC Transfusions From Chemo-Induced AEs in ES-SCLC

October 19th 2020

Treatment with the CDK4/6 inhibitor trilaciclib prior to chemotherapy compared with placebo significantly reduced the need for supportive care interventions in the management of severe neutropenia and grade 3/4 anemia induced by chemotherapy in patients with extensive-stage small cell lung cancer.

Investigators Tackle New NSCLC Target With Glutaminase Inhibitor

October 19th 2020

Telaglenastat, a novel drug that targets a key metabolic pathway, has shown encouraging antitumor activity in several cancer types.

IDE196/Crizotinib Combo Under Exploration in GNAQ/11+ Solid Tumors

October 18th 2020

An ongoing, collaborative clinical trial has been expanded to evaluate the investigational protein kinase C inhibitor IDE196 in combination with the multikinase inhibitor crizotinib (Xalkori) for patients with GNAQ- or GNA11-mutated solid tumors, including metastatic uveal melanoma , skin melanoma, lung cancer, and colorectal cancer.

Dr. Aggarwal on Investigational Biomarkers in Lung Cancer

October 16th 2020

Charu Aggarwal, MD, MPH, discusses investigational biomarkers in lung cancer.

Navigating Newfound Options in SCLC With Immunotherapy and Lurbinectedin

October 16th 2020

Rafael Santana-Davila, MD, discusses the introduction of immunotherapy and lurbinectedin to the SCLC armamentarium, as well as areas in need of additional research.

RET Inhibitor Enters the Therapeutic Ring in Multiple Settings

October 14th 2020

Todd Bauer, MD, discusses how the highly specific nature of selpercatinib leads to greater tolerability than multityrosine kinase inhibitors and its frontline potential.

PD-1/CTLA-4 Combos, Broader Patient Population Are Next Steps With Immunotherapy in Locally Advanced NSCLC

October 12th 2020

David Gerber, MD, highlights the impact of the PACIFIC trial and other next steps with immunotherapy in patients with stage III NSCLC.

Next Steps in Small Cell Lung Cancer Feature Closer Eye on Immunotherapy, Lurbinectedin

October 8th 2020

Benjamin Drapkin, MD, PhD, discusses the road ahead in small cell lung cancer research, and the challenges that still need to be solved in the first- and second-line settings.

PD-1 Inhibition Reigns Supreme in Advanced Squamous NSCLC

October 7th 2020

Ronan J. Kelly, MD, MBA, explains how the results of the KEYNOTE-407 trial have positioned pembrolizumab plus chemotherapy as the frontline standard of care in this setting.

Neoadjuvant Nivolumab/Chemo Combo Significantly Improves pCR in Resectable NSCLC

October 7th 2020

The combination of nivolumab plus chemotherapy resulted in a statistically significant improvement in pathologic complete response when used as neoadjuvant treatment in patients with resectable non–small cell lung cancer, meeting the primary end point of the phase 3 CheckMate-816 trial.

Sotorasib Shows Durable Antitumor Activity in KRAS G12C–Mutant Advanced NSCLC

October 6th 2020

Sotorasib demonstrated durable responses in patients with KRAS G12C–mutated advanced non–small cell lung cancer who had progressed on a median of 2 previous lines of treatment.

Mobocertinib Continues to Show Clinical Activity in EGFR Exon 20–Mutant NSCLC

October 5th 2020

Mobocertinib elicited a 43% objective response rate and an 86% disease control rate in select patients with non–small cell lung cancer who have EGFR exon 20 insertion mutations.

Dr. Gainor on the Evolving Lung Cancer Armamentarium

October 5th 2020

Justin F. Gainor, MD, discusses the evolving lung cancer armamentarium.